Monday, October 17, 2011

ChemoCentryx refiles IPO plans, seeks to raise $69M

ChemoCentryx Inc. has refiled plans for an initial public offering to raise $69 million, according to a regulatory filing with the U.S. Securities and Exchange Commission.
The Mountain View-based company, which develops oral drugs for autoimmune diseases, inflammatory diseases and oncology, filed for a $57.5 million IPO in 2007, but withdrew the registration citing market conditions. It had hoped to use most of the proceeds to develop treatment of inflammatory bowel disease, and for research and development of other candidates.

No comments:

Post a Comment